MONETIZATION OF ADDITIONAL BENEFIT OF ORPHAN DRUGS IN GERMAN ARBITRATION BOARD DECISIONS

被引：0
|
作者：
Ladicke, N. [1 ]
Fieke, H. [1 ]
Volmer, T. [1 ]
机构：
[1] SmartStep Consulting GmbH, Hamburg, HH, Germany
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMU73
引用
收藏
页码：S720 / S720
页数：1
相关论文
共 50 条
  • [1] UPDATE ON IMPACT OF THE ADDITIONAL BENEFIT EXTENT OF ORPHAN DRUGS ON PRICE NEGOTIATIONS IN THE GERMAN OUTPATIENT SECTOR
    Freiberg, M.
    Schwarz, R.
    Schalk, E.
    Kraft, T.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A568 - A568
  • [2] HOW DOES THE ADDITIONAL BENEFIT EXTEND OF ORPHAN DRUGS IMPACT PRICE NEGOTIATIONS IN THE GERMAN OUTPATIENT SECTOR?
    Schwarz, R.
    Freiberg, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A600 - A600
  • [3] HOW DOES THE ADDITIONAL BENEFIT EXTENT OF ORPHAN DRUGS IMPACT PRICE NEGOTIATIONS IN THE GERMAN OUTPATIENT SECTOR?
    Freiberg, M.
    Schwarz, R.
    Fath, F.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A550 - A550
  • [4] COMPARISON OF ADDITIONAL BENEFIT RATING AND DRUG PRICES FOR ORPHAN DRUGS IN FRANCE AND GERMANY
    Oku, Y.
    Fukushima, A.
    Dorey, J.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [5] Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit
    Kleining, Katrin
    Laufenberg, Jan
    Thrun, Philip
    Ehlert, Dorothee
    Wasem, Juergen
    Bartol, Arne
    [J]. HEALTH ECONOMICS POLICY AND LAW, 2024, 19 (02) : 216 - 233
  • [6] GERMAN EARLY BENEFIT ASSESSMENTS OF ORPHAN DRUGS UNDER FULL DOSSIER CONDITIONS
    Kirchmann, T.
    Schoenermark, M.
    Ewald, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S199 - S199
  • [7] RE-ASSESSEMENT OF ORPHAN DRUGS IN GERMAN BENEFIT ASSESSMENT AFTER EXCEEDING 50-M-EURO SALES: EFFECTS ON ADDITIONAL BENEFIT AND REIMBURSEMENT PRICE
    Ernst, N.
    Ecker, T.
    [J]. VALUE IN HEALTH, 2019, 22 : S858 - S858
  • [8] From the north German arbitration board
    Leitz, K. H.
    Neu, J.
    [J]. THORACIC AND CARDIOVASCULAR SURGEON, 2007, 55 (04): : B37 - B38
  • [9] From the North German arbitration board
    Leltz, K. H.
    Neu, J.
    [J]. THORACIC AND CARDIOVASCULAR SURGEON, 2007, 55 (03): : B25 - B26
  • [10] OUTCOMES OF BENEFIT ASSESSMENTS OF ORPHAN DRUGS WITHOUT ORPHAN DESIGNATION IN GERMANY
    Frick, L.
    Qiu, Z.
    Schoenermark, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S305 - S305
12345